Bioretec refines its financial goal regarding sales margin

A health technology company Bioretec will switch to reporting the adjusted gross margin in accordance with industry reporting practices instead of the previously reported gross margin. The new reporting practice will be implemented from the first quarter of the current year.

Bioretec will publish its first quarter results on Friday, May 15.

With the reporting change, the second financial goal of the strategy period 2026-2028 will be updated to include the adjusted net sales margin instead of the previously reported net sales margin.

Bioretec’s new financial goals for the current strategy period are to achieve a turnover of more than ten million euros by 2028 and maintain an average adjusted gross profit margin of more than 70 percent during the strategy period.

Adjusted gross margin describes the profitability of the company’s implant sales before costs related to commercialization, such as sales commissions. The change improves the transparency of Bioretec’s core business performance and ensures consistency with industry practices.

The calculation formula for the previously reported sales margin was the total turnover minus the change in inventories and materials and services. In the future, the turnover component will only include turnover from the sale of implants, and commissions and external services of a fixed nature will be recorded below the adjusted gross margin.